Formulation: A solid
Formal Name: 4-[[(4-carboxybutyl)[2-[5-fluoro-2-[[4′-(trifluoromethyl)[1,1′-biphenyl]-4-yl]methoxy]phenyl]ethyl]amino]methyl]-benzoic acid
Purity: ≥95%
Formula Markup: C35H33F4NO5
Formula Weight: 623,6
Shelf life (days): 1460
CAS Number: 1027642-43-8
Notes: BAY 60-2770 is an activator of soluble guanylate cyclase (sGC; EC50s = 592 and 573 nM for the α1β1 and α2β1 isoforms, respectively).{51942} It increases cGMP levels in, and inhibits the aggregation of, collagen- or thrombin-activated washed isolated human platelets, effects that can be potentiated by ODQ (Item No. 81410).{51943} BAY 60-2770 (10 µM) inhibits doxorubicin-induced decreases in the viability of, and increases in reactive oxygen species (ROS) levels in, H9c2 cardiomyocytes in an in vitro model of cardiotoxicity.{51944} It decreases pulmonary and systemic arterial pressure in a rat model of pulmonary hypertension induced by monocrotaline (Item No. 16666).{51945} BAY 60-2770 (1 mg/kg) reduces eosinophil infiltration into bronchoalveolar lavage fluid (BALF) and lung tissue in an ovalbumin-sensitized mouse model of allergic airway inflammation.{51946} It reverses obesity-induced increases in the frequency of voiding and non-voiding bladder contractions in mice fed a high-fat diet when administered at a dose of 1 mg/kg.{51947}
Deutsch
English
